Lancet oncol: Biomarkers guide the effectiveness of treatment for non-small cell lung cancer

Lung Cancer Master Program (Lung-MAP; S1400) is a complete biomarker-driven master program designed to address the unsolved need for better treatment of squamous non-small cell lung cancer.
created Run-MAP (S1400) to establish a foundation for rapid regulatory assessment of biomarker screening and targeted treatment, it is the first biomarker-driven major program initiated by the National Cancer Institute (NCI).
-MAP (S1400) was completed through public-private partnerships in NCI's national clinical trial network.
were included in IV or relapsed squamous non-small cell lung cancer patients who had under the age of 18 and had previously underwent platinum-based chemotherapy.
June 16, 2014 - January 28, 2019, 1,864 patients were recruited, of whom 1,841 (98.9%) provided tissue.
of the 1,841 patients who provided the tissue, 1,674 (90.9%) had biomarker test results, of which 1,404 (83.9%) were grouped according to biomarker results.
group of patients, 655 (46.7%) were studied in subgroups.
subgroup study, driven by biomarkers, evaluated taselisib (targeted PIK3CA mutation), Pabosini (cell cycle gene variant), AZD4547 (EGFR variant), rilotumumab combined elotini (MET), talazoparib (same-source recombination repair defect) and telisotuzumab vedotin (MET).
non-matching subgroup studies evaluated the degree-va-mono-resistance, navu-mono-anti-combined ipi monoanti (anti-PD-1 or PD-L1 primary disease) and the degree-logging monoantigen combined tremelimumab (anti-PD-1 or PD-L1 recurring diseases).
combined subgroup study data, 7 out of 143 patients (7.0%) responded to targeted treatment, 53 out of 315 patients (16.8%) responded to PD-1 or PD-L1 treatment (primary immunotherapy disease), and 3 out of 56 patients (5.4%) responded to dorsey secondary therapy.
survival was 5.9 months in the targeted treatment group, 7.7 months in the dossythal group and 10.8 months in the anti-PD-1 or anti-PD-L1 group.
progress-free survival of the three groups was 2.5 months, 2.7 months and 3.0 months, respectively.
Lung-MAP (S1400) has achieved its goal of rapidly addressing biomarker-driven treatment for squamous non-small cell lung cancer.
the beginning of 2019, a new screening programme was implemented to extend screening to all histological types of non-small cell lung cancer and to increase the combined immunotherapy programme against PD-1 and anti-PD-L1 for relapsed diseases.
these changes, Lung-MAP will continue to achieve its goals and focus on unsealed needs in the treatment of advanced lung cancer.